Slides
Page 1
1 © 2025 Artivion, Inc. Corporate Overview November 2025
Page 2
2 2 FORWARD-LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management’s beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our belief that we can continue to drive sustained double digit revenue growth and EBIDTA growth at twice the rate of revenue growth, as a result of our base business, our high growth On-X and stent graft businesses and our leverageable global infrastructure; our estimates of the size of the total addressable markets and growth profiles for our preservation services (human tissue), mechanical heart valves, stents and surgical sealants; our estimates of the size of the total addressable markets and growth rates for E-vita OPEN NEO, AMDS, NEXUS, E-nside, Artivex and E-tegra; our estimates relating the conduct of and timelines for enrollment of our ongoing and planned clinical trials and regulatory approvals, including PERSEVERE, Endospan’s TRIOMPHE, and for ARCEVO and TAAA Systems; our beliefs that our products will result in improved patient outcomes; our expectations regarding future constant currency revenue growth in 2025 compared to 2024; our estimates and related expectations regarding increased incremental cash flow by revenue growth and gross margin and adjusted EBITDA margin expansion; our expectation that we will achieve be free cash flow positive and the timing thereof; our expectation that we will decrease net debt leverage by year end 2025; and our belief and expectations about our future revenue, year over year growth and growth drivers, earnings, adjusted EBITDA and other financial measures and related information. These forward-looking statements are subject to a number of risks, uncertainties, estimates and assumptions that may cause actual results to differ materially from current expectations, including but not limited to the risks and uncertainties relating to our international operations; regulatory developments; clinical trials and regulatory approvals; anticipated benefits of our credit facility and other agreements; market opportunities and commercialization; and the November 2024 cybersecurity incident. These risks and uncertainties include the risk factors detailed in documents that we file with or furnish to Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2024, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise. © 2025 Artivion, Inc.
Page 3
3 AN AORTIC DISEASE-FOCUSED COMPANY ~$400 MILLION FY24 REVENUE; ~$70 MILLION FY24 EBITDA © 2025 Artivion, Inc. AORTIC VALVE STENOSIS <65 YRS ALLOGRAFT VALVES MECHANICAL VALVES AORTIC DISSECTION & ANEURYSMS STENT GRAFTS SURGICAL SEALANT Dissection Aneurysm
Page 4
4 John Davis Chief Commercial Officer Jean Holloway SVP, GC, CCO & CS Marshall Stanton SVP, Clinical Research & Chief Medical Officer 4 Decades of combined experience and leadership in the medical device industry. EXPERIENCED LEADERS © 2025 Artivion, Inc. Robert Thomson VP, Research & Development Drew Green SVP, Regulatory Affairs and Quality Pat Mackin Chairman, President & CEO Previously with Lance Berry EVP, COO & CFO
Page 5
5 DRIVING SUSTAINED DOUBLE-DIGIT REVENUE GROWTH & 2x+ EBITDA GROWTH © 2024 Artivion, Inc. Stent Grafts On-X Heart Valves Surgical Sealants Other Preservation Services Double Digit Revenue Growth 2x+ EBITDA Growth Gross margin expansion through mix ~200 direct sales employees globally Global G&A Infrastructure Highly Differentiated, Highly Defendable Base Business High Growth, High Margin Businesses Gross Margin Expansion + SG&A Leverage 22%19% 25% Data for Full Year Ended December 31, 2024 32%
Page 6
6 Differentiation 2024 Revenue Global TAM Market Position/ Share # Major Competitors Growth Profile Preservation Services (CryoValve® SG) Only Decellularized Pulmonary Valve $98M $150M #1 / 65% 2 Mid Single Digit Surgical Sealant (BioGlue) Only Cardiac Sealant with Acute Type A Dissection Indication $74M $260M #2 / 28% 3 Mid Single Digit HIGHLY DIFFERENTIATED, HIGHLY DEFENDABLE BASE BUSINESS Strong Positions in Segments with Limited Competition and No Anticipated New Entrants *Low INR of 1.5 – 2.0, reduce INR after 3 months of standard therapy **3 competitors total, but 2 with less than 5% combined market share © 2025 Artivion, Inc.
Page 7
7 ON-X AORTIC HEART VALVE POST APPROVAL STUDY (PAS) VS. PROACT IDE © 2025 Artivion, Inc. 5-year real-world results demonstrate even better patient outcomes than predicted by the On-X aortic heart valve PROACT IDE study COMPOSITE PRIMARY ENDPOINT 5.39% vs 1.83%, p<0.0001; N=229 Reduction in Major Events** 66% 28% 5.39% 1.83% Reduction in Major Bleeding 87% 60% INR Monitoring Method (% Clinic / % Home) 84% / 16% 0% / 100% Post Approval Study (5 Years)1 PROACT IDE Study2 Thromboembolism Valve Thrombosis Major Bleeding 1. Gerdisch, et al. for the On-X Aortic Post-Approval Study Investigators. (2024, April 27-30) Low-Dose Warfarin with a Novel Mechanical Aortic Valve: Interim Registry Results at 5-Year Follow-up. [Presentation]. AATS. Toronto, Canada. 2. Puskas J, et. al. (2014). Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the Prospective Randomized On- X® Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg, 147(4), 1201- 11. *Artivion data on file, weighted average of control groups from FDA Premarket Approval P000037 S030 and IDE trial G050208. **Composite of Thromboembolism, Valve Thrombosis, and Major Bleeding Only Mechanical Heart Valve Maintained at a Low INR of 1.5 to 2.0
Page 8
8 ON-X MECHANICAL VALVE: UNIQUELY POSITIONED FOR YOUNGER AVR PATIENTS TAVR was associated with a 2.3-fold increased hazard (+130%) of 6-year mortality when compared to SAVR in patients <65.1 1. 1. Alabbadi S, Bowdish ME, Sallam A, Tam DY, Hassan I, Kumaresan A, Alzahrani AH, Iribarne A, Egorova N, Chikwe J, Transcatheter versus Surgical Aortic Valve Replacement in Patients Younger than 65 Years in the US, The Journal of Thoracic and Cardiovascular Surgery (2025), doi: https://doi.org/10.1016/j.jtcvs.2024.12.025. 2. Bowdish ME, Mehaffey JH, Chang S-C, O’Gara P, Mack MJ, Goldstone A, Chikwe J, Gillinov AM, Wu C, Fontana G, Bavaria J, Malaisrie C, Kaneko T, Sultan I, von Ballmoos MW, Harrington K, Jacobs J, Thourani V, Szeto W, Sabik J, Habib R, Badhwar V, Bioprosthetic vs. Mechanical Aortic Valve Replacement in Patients 40-75 Years. Journal of American College of Cardiology (2025) doi: https://doiˌorg/10ˌ1016/jˌjaccˌ2025ˌ01ˌ013. 3. Gerdisch MW, et al. Low-Dose Warfarin with a Novel Mechanical Aortic Valve: Interim Registry Results at 5-Year Follow-Up, J Thorac Cardiovasc Surg (2024), doi: https://doi.org/10.1016/j.jtcvs.2024.04.017. 2. Artivion data on file, weighted average of control groups from FDA Premarket Approval P000037 S030 and IDE trial G050208. SAVR > TAVR in patients younger than 65 years On-X > Other Mechanical Valves with differentiated, validated clinical benefit3 At a lower INR target (1.5-2.0), On-X Aortic valve demonstrated an 87% decrease in major bleeding with no increase in thromboembolism and zero valve thrombosis when compared to standard anticoagulation therapy (INR 2.0-3.0).3 Mechanical AVR > Bioprosthetic AVR in patients 60 years and younger 10-year all-cause mortality favors mechanical valves in patients ≤60 (independently risk- adjusted)2 when compared to bioprosthetic valves for AVR. NEW $100M U.S. Market Opportunity
Page 9
9 ON-X LOW INR INDICATION DRIVING DURABLE DOUBLE-DIGIT GROWTH & SHARE GAINS* ARTIVION ABBOTT*Market share estimates derived from 2024 IQVIA Medical device supply audit and historical sales reports. Excludes MDT and CORCYM which combined are estimated to be <4% of total market share in 2024. YTD On-X Sales Growth as of September 30, 2025 and future On-X market share expectations are not to scale © 2025 Artivion, Inc. Growth Accelerated by New Clinical Data Unlocking New Incremental $100M U.S. Market 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 30% 62%70% 34% Original Approval of Low INR Claim YTD FY25 ON-X SALES 20% GROWTH Y/Y
Page 10
10 Mature Stent Graft Segment 10 Focused on More Complex, Less Competitive Segments Artivion Stent Graft Growth: 16% 3-year CAGR Iliac (E-liac ) $140M Global TAM Frozen Elephant Trunk (E-vitaTM Open Neo) $250M Global TAM Acute Type A Dissection (AMDS ) $540M Global TAM Endovascular Arch Branched System (NEXUS®) $600M Global TAM Thoracoabdominal (E-nsideTM / Extra Design) $480M Global TAM Abdominal (E-tegra) $1.3B Global TAM Thoracic (ArtivexTM) $700M Global TAM © 2025 Artivion, Inc. HIGH GROWTH STENT GRAFT BUSINESS Advanced Stent Graft Segment $2B TAM $2B TAM Crowded Competitive Market Note: Market sizes are approximate MARKET GROWTH RATE: MID-TEENS MARKET GROWTH RATE: MID-SINGLE DIGITS
Page 11
11 HUMANITARIAN DEVICE EXEMPTION ENABLES EARLY U.S. LAUNCH OF AMDSTM High Growth, High Margin Business with Limited Competitive Alternatives Strong Early Market Traction with Unparalleled Clinical Benefits Supported by Growing Body of Evidence New MS-DRG Code 209, effective October 1, 2025 PMA Approval Expected Mid-2026 1 2 1 2 PTFE felt cuff: strengthens the aortic tissue in preparation to perform the conventional polyester graft to aorta anastomosis. Uncovered nitinol wire braided stent: stabilizes aortic wall and promotes remodeling 1.Adjudicated data as presented at the 61st STS Annual Meeting by Dr. S. Fukuhara on behalf of corresponding authors, One- Year Results of a Novel Aortic Arch Hybrid Prosthesis for Open Repair of Acute DeBakey Type I Dissection with Malperfusion in the PERSEVERE Study / Friday, January 24, 2025 / 10:00 am – 10:15 am. 2.Bozso SJ, N. J., Chu MWA, Kiaii B, El-Hamamsy I, Ouzounian M, Forcillo J, Kempfert J, Stark C, Moon MC. (2022). 3-Year Outcomes of the Dissected Aorta Repair Through Stent Implantation Trial. J Thorac Cardiovasc Surg. $150 Million Addressable Market Opportunity
Page 12
12 ACUTE DEBAKEY TYPE I (ADTI) WITH MALPERFUSION Hemiarch Reference Cohort Avg.¹ (n=790) PERSEVERE² (n=93) 58.0% >=1 MAE 26.9% 34.6% All-Cause Mortality 9.7% 20.9% New Disabling Stroke 10.8% 24.1% Renal Failure Requiring Dialysis 19.4% 10.5% Myocardial Infarction 0.0% 45.0% Distal Anastomotic New Entry 0.0% Full 30-Day Data Through Hospital Discharge Data Full IDE data demonstrates AMDS use significantly lowers 30-day Major Adverse Events (MAEs) compared to hemiarch control AMDSTM PERSEVERE US IDE Study Primary Endpoints Total patients with ≧ 1MAE PERSEVERE: 27% Goal: < 40% © 2025 Artivion, Inc. 30-day data demonstrate AMDS induced positive aortic remodeling in over 80% of patients3 1. Zindovic I, 2019. Pacini D, 2013. Girdauskas E, 2009. Geirsson A, 2007. and Bossone E, 2002. 2. Szeto WY, Fukuhara S, Fleischman F, Sultan I, Brinkman W, Arnaoutakis G, Takayama H, Eudailey K, Brinster D, Jassar A, DeRose J, Brown C, Farrington W, Moon MC. A novel hybrid prosthesis for open repair of acute DeBakey type I dissection with malperfusion: Early results from the PERSEVERE trial. J Thorac Cardiovasc Surg. 2024 Aug 6:S0022-5223(24)00677-9. 3. Adjudicated data as presented at AATS April 2024, manuscript pending publication
Page 13
13 R&D PIPELINE Endovascular Arch Branch System Hybrid Acute Type A Dissection (ATAD) Prosthesis Hybrid Frozen Elephant Trunk AMDS Endospan’s NEXUS Arcevo LSA Endovascular Thoracoabdominal System $150M ~$1 B TOTAL OPPORTUNITY © 2025 Artivion, Inc. US PMA* $75MJapan $150MUS PMA $100MJapan $80MUS PMA $50MJapan $325MUS PMA $50MEU > 2029 > 2029 > 2029 Regulatory Path Addressable Market 2025 2026 2027 2028 2029 *AMDS is commercially available in the U.S. following receipt of Humanitarian Device Exemption
Page 14
14 Endospan NEXUS ® TRIOMPHE US IDE Trial 30-day data demonstrate 63% reduction in major adverse event (MAE) rate compared to the reference performance goal PROJECT STATUS (FORECAST COMPLETIONS) Enrollment 4Q24 Follow Up 4Q25 Approval 2H26 © 2025 Artivion, Inc. 30-DAY DATA 1 TRIOMPHE (n=54) Performance Goal p Value MAEs2 >=1 13.0% 35.0% p<0.001 Technical Failure 1.9% 30.0% p<0.001 Source: Endospan Ld 1. References for PG: Bashir et al. Aorta 2014; Brat et al. JCTS, 2015; Chakos et al. Ann Cardiothorac Surg 2018; DeRango et al. J Vasc Surg 2015; Hiraoka et al. JTCVS, 2017; Iba et al. JTCVS 2013; Joo et al. JTCVS 2018; Thomas et al. JTCVS, 2012 2. MAE includes: Early Mortality, Disabling Stroke, Permanent Paralysis/Paraplegia, Renal Failure (Permanent Dialysis), Aortic R upture Presented at AATS 2025 KEY TAKEAWAYS • FDA investigational device exemption (IDE) trial for endovascular treatment of chronic dissections in the aortic arch; focused on patients at high risk for open surgery • 30-day data demonstrates statistically significant improvement in clinical outcomes and device technical performance compared with performance goals set forth in the FDA- approved IDE • Stroke and renal failure rates particularly favorable compared to published data for alternative endovascular treatments
Page 15
15 ARTIZEN PIVOTAL IDE STUDY Prospective, Non-randomized, Non-blinded, Double-arm, Multicenter (US & EU ≈ 30 Sites) PRIMARY PATIENT GROUP 117 patients: Chronic dissection or Aneurysm Primary endpoint: Freedom from major adverse events (MAEs) within 1-year post-index procedure: all-cause mortality, new permanent disabling stroke, new permanent paraplegia and/or paraparesis, unanticipated aortic reoperation in the treated segment, LSA occlusion SECONDARY PATIENT GROUP 15 patients: Acute or subacute dissection Descriptive statistics: No pre-defined endpoint STUDY STATUS 1ST Enrollment Nov 2025 Enrollment ∼ 2025- 2027 Follow Up ∼ 2027- 2028 Approval ∼ 2029 REFERENCE COHORT Historical controls freedom from MAE rate of 59%. Positive outcome is freedom from MAE composite ≥74% © 2025 Artivion, Inc.
Page 16
16 Highly Accretive Product Pipeline Increased U.S. Mix Benefit from AMDS HDE Approval and On-X Market Expansion Expected Double Digit Revenue Growth DIFFERENTIATED BUSINESS MODEL WITH HIGHLY LEVERAGEABLE GLOBAL INFRASTRUCTURE © 2025 Artivion, Inc. Significant EBITDA Margin Expansion Opportunity Gross Margin Expansion ~200 Global Direct Sales Employees Focused on Cardiac/Vascular Surgeons Treating Aortic Disease Minimal Case Support Required Demonstrated Leverage: 10% 3-year CC Revenue CAGR vs 5% Direct Sales Employee Headcount CAGR Scalable Global Sales Force Consistent investment of 7- 8% of sales Strong Balance Sheet Enables Self-Funding of Best-in-Class Pipeline to Unlock Incremental Market Opportunities Reinvesting in R&D Leverageable Global G&A Infrastructure Public Company Since 1993 No Major Location Additions Since 2017 ~1,700 Employees Worldwide
Page 17
17 s EBITDA MARGIN EXPANSION & DELEVERAGING © 2025 Artivion, Inc. 2022 2023 2024 *Graphs are not to scale **2025 data assumes midpoint of guidance as of November 6, 2025, and net debt following recent exchange of the convertible notes on May 28, 2025. 6.7x 4.8x 3.8x 13% 15% 18% ADJUSTED EBITDA MARGIN NET DEBT LEVERAGE 2025 20% 2022 2023 2024 6.7x 4.8x 3.8x <2.0 2025 1.8x NET DEBT As of Sep 30, 2025 Supported by Strong Balance Sheet & Prudent Capital Management
Page 18
18 FULL YEAR 2025 REVENUE GUIDANCE © 2025 Artivion, Inc. GROWTH DRIVERS + Continued strength in existing products On-X and aortic stents + Positive new data supporting the benefits of AMDS and On-X aortic valves + Launch of AMDS following receipt of Humanitarian Device Exemption by the FDA $388.5M 9.4% $420M- $435M 10-14% $423M- $435M 11-14% $435M- $443M 12-14% $439M- $445M 13-14% FY24 Results Initial Revenue ($) Y/Y cc. Growth (%) Current FY25 Guidance Revised Q1 Revised Q2
Page 19
19 Expect continued operating leverage to be driven by gross margin expansion, global sales force and G&A infrastructure Revenue growth and adjusted EBITDA margin expansion drives incremental cash flow DRIVERS FULL YEAR 2025 ADJUSTED EBITDA EXPECTATIONS REVENUE GROWTH AND OPERATING LEVERAGE TO DRIVE ADJUSTED EBITDA EXPANSION © 2025 Artivion, Inc. $71.3M 32% $84M- $91M 18-28% $86M- $91M 21-28% $88M- $91M 24-28% FY24 Results Initial Adj. EBITDA ($) Y/Y Growth (%) Current FY25 Guidance Revised Q2
Page 20
© 2025 Artivion, Inc.